Docket No.

264837US0X PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Kenichi KOYAKUMARU, et al.

SERIAL NO: 10/521,800 GAU: 1625

FILED: August 2, 2005 EXAMINER: FOR: PROCESS FOR PRODUCING 5-(2'-PYRIDYL)-2-PYRIDONE DERIVATIVE

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the reference(s) cited in the attached Supplementary European Search Report and listed on the attached form PTO-1449. Copies of the listed reference(s) are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language reference(s).
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Norman F. Oblon

Customer Number

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 05/03) Jay E. Rowe, Jr. Registration No. 58, 948 1FW

				/	OPE	883 1	SHE	ET	1 (OF	1
				LATTIC DOOUST NO	UI FO HUI	<u> </u>	OCDIAL I	···			
Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO.	40°	5/	SERIAL I					
				264837US0X PC	TO THE PARTY OF		10/521,	800			
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT TABLE OF THE PARTY OF							
LIST OF REFERENCES CITED BY AFFLICANT			Kenichi KOYAKU								
				FILING DATE			GROUP				
				August 2, 2005			1625				
			ENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	SUB		ILING APPRO		
	AA										
	AB										
	AC										
	AD										
	AE										
	AF										
	AG										
	AH					-					
	Al										
	AJ		ļ								
	AK										
	AL										
	AM										
	AN		<u> </u>								
FOREIGN PATENT DOCUMENTS											
		DOCUMENT NUMBER	DATE	COUNTRY			TRANSLATION YES NO				
	AO		ļ								
	AP				. 10						
	AQ										
	AR										
	AS										
	AT										
	AU										
	AV		<u> </u>		-						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)											
	AW	John R. PROUDFOOT, et al. "NOVEL NON-NUCLEOSIDE INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) REVERSE TRANSCRIPTASE. 4.1 2-SUBSTITUTED DIPYRIDODIAZEPINONES AS POTENT INHIBITORS OF BOTH WILD-TYPE AND CYSTEINE-181 HIV-1 REVERSE TRANSCRIPTASE ENZYMES", JOURNAL OF MEDICINAL CHEMISTRY, XP-002031262, Vol. 38, No. 24, 1995, Pages 4830-4838									
	AX				-						
	AY		-								
	AZ						Additional References sheet(s) attached				
Examiner				•••		Date Considered					
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in											
conformance	and no	eference is considered, v ot considered. Include co	whether or not py of this form	i citation is in conformat i with next communicat	ion to applicant.	, Draw III	ne urrough	citation	ı ıı not	ш	